NYSE American - Delayed Quote USD

Apimeds Pharmaceuticals US, Inc (APUS)

1.8100
-0.3900
(-17.73%)
At close: May 12 at 3:59:55 PM EDT
1.9600
+0.15
+(8.29%)
Pre-Market: 6:35:54 AM EDT
Loading Chart for APUS
  • Previous Close 2.2000
  • Open 2.2400
  • Bid 1.8800 x 1300
  • Ask --
  • Day's Range 1.7350 - 2.2800
  • 52 Week Range 1.7200 - 4.0000
  • Volume 378,042
  • Avg. Volume 1,030,994
  • Market Cap (intraday) 22.975M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1200
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey.

www.apimedsus.com

2

Full Time Employees

December 31

Fiscal Year Ends

Recent News: APUS

View More

Performance Overview: APUS

Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

APUS
54.75%
S&P 500 (^GSPC)
0.64%

1-Year Return

APUS
54.75%
S&P 500 (^GSPC)
11.90%

3-Year Return

APUS
54.75%
S&P 500 (^GSPC)
48.70%

5-Year Return

APUS
54.75%
S&P 500 (^GSPC)
103.62%

Compare To: APUS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: APUS

View More

Valuation Measures

Annual
As of 5/12/2025
  • Market Cap

    22.98M

  • Enterprise Value

    23.57M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -366.30%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -1.39M

  • Diluted EPS (ttm)

    -0.1200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.46k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -294k

Research Analysis: APUS

View More

Company Insights: APUS

Research Reports: APUS

View More

People Also Watch